USD
$0.00
(0.00%
)At Close (As of Sep 3, 2025)
$149.23M
Market Cap
-
P/E Ratio
-1.48
EPS
$5.31
52 Week High
$1.84
52 Week Low
LIFE SCIENCES
Sector
Field | Value (USD) |
---|---|
Gross Profit | -$229K |
Total Revenue | $0 |
Cost Of Revenue | $229K |
Costof Goods And Services Sold | $229K |
Operating Income | -$39M |
Selling General And Administrative | $16M |
Research And Development | $23M |
Operating Expenses | $39M |
Investment Income Net | - |
Net Interest Income | $176K |
Interest Income | $2.4M |
Interest Expense | $2.2M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $229K |
Income Before Tax | -$40M |
Income Tax Expense | -$40M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$40M |
Comprehensive Income Net Of Tax | - |
Ebit | -$38M |
Ebitda | -$37M |
Net Income | -$40M |
Field | Value (USD) |
---|---|
Total Assets | $39M |
Total Current Assets | $36M |
Cash And Cash Equivalents At Carrying Value | $13M |
Cash And Short Term Investments | $13M |
Inventory | - |
Current Net Receivables | - |
Total Non Current Assets | $2.2M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $974K |
Intangible Assets Excluding Goodwill | $974K |
Goodwill | $1M |
Investments | - |
Long Term Investments | - |
Short Term Investments | $22M |
Other Current Assets | $2.1M |
Other Non Current Assets | - |
Total Liabilities | $18M |
Total Current Liabilities | $6.7M |
Current Accounts Payable | $2M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $110K |
Total Non Current Liabilities | $11M |
Capital Lease Obligations | $121K |
Long Term Debt | $9.8M |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $10M |
Other Current Liabilities | $4.6M |
Other Non Current Liabilities | $1.1M |
Total Shareholder Equity | $21M |
Treasury Stock | - |
Retained Earnings | -$206M |
Common Stock | $103K |
Common Stock Shares Outstanding | $32M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$30M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $229K |
Capital Expenditures | $0 |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | -$22M |
Cashflow From Financing | $49M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | $0 |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$40M |
Field | Value (USD) |
---|---|
Gross Profit | -$229K |
Total Revenue | $0 |
Cost Of Revenue | $229K |
Costof Goods And Services Sold | $229K |
Operating Income | -$39M |
Selling General And Administrative | $16M |
Research And Development | $23M |
Operating Expenses | $39M |
Investment Income Net | - |
Net Interest Income | $176K |
Interest Income | $2.4M |
Interest Expense | $2.2M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $229K |
Income Before Tax | -$40M |
Income Tax Expense | -$40M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$40M |
Comprehensive Income Net Of Tax | - |
Ebit | -$38M |
Ebitda | -$37M |
Net Income | -$40M |
Sector: LIFE SCIENCES
Industry: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and markets cytisinicline for smoking and nicotine addiction cessation in the United States and internationally. The company is headquartered in Vancouver, Canada.